Related Experiment Video
Updated: Apr 23, 2026
Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy: Advances, Translational Barriers, and
Julie R Youssef1, Esraa M Elgammal2, Dina M Mahdy1
1Pharmaceutics Department, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Alamein, Egypt.
Abstract:
Breast cancer remains the most prevalent malignancy among women worldwide and a major cause of cancer-related mortality. Despite remarkable progress in molecularly targeted and immune-based therapies, therapeutic resistance, dose-limiting systemic toxicity, and inefficient drug delivery continue to hinder clinical outcomes, particularly in aggressive subtypes such as triple-negative breast cancer. Exosomes, naturally secreted nanosized vesicles, have emerged as a transformative platform owing to their biocompatibility, intrinsic targeting capability, and ability to transport diverse therapeutic cargos across biological barriers. Recent advances in exosome biology, engineering, and isolation technologies have reignited interest in their clinical exploitation as drug delivery systems. However, translation into clinical oncology remains in its early stages. This review provides a comprehensive overview of exosome-based drug delivery systems specifically within the context of breast cancer therapy, critically evaluating their sources, isolation techniques, cargo loading strategies, targeting mechanisms, and formulation considerations. It also examines preclinical findings demonstrating enhanced therapeutic efficacy and reduced off-target toxicity, alongside the limited yet growing number of clinical trials investigating exosome therapeutics in solid tumours. Importantly, the review identifies major gaps, including lack of standardized manufacturing protocols, incomplete pharmacokinetic understanding, and unresolved safety concerns, that currently impede clinical translation. By bridging molecular insights with translational perspectives, this work underscores the untapped potential of exosomes as next-generation drug carriers in breast cancer. It highlights the urgent need for harmonized methodologies, scalable production systems, and regulatory frameworks to enable their safe and effective integration into future cancer therapeutics.
Insights
Exosomes show promise as drug delivery systems for breast cancer, offering enhanced efficacy and reduced toxicity. Further research and standardized methods are needed for clinical translation of these nanovesicles.
Area of Science:
- Oncology
- Nanotechnology
- Biotechnology
Background:
- Breast cancer is a leading cause of mortality globally, with existing therapies facing challenges like resistance and toxicity.
- Exosomes, natural nanovesicles, offer biocompatibility and drug transport capabilities, presenting a novel therapeutic platform.
- Triple-negative breast cancer, an aggressive subtype, particularly requires innovative treatment strategies.
Purpose of the Study:
- To provide a comprehensive review of exosome-based drug delivery systems for breast cancer therapy.
- To critically evaluate sources, isolation, loading, targeting, and formulation of exosomes for therapeutic applications.
- To identify challenges and future directions for the clinical translation of exosome therapeutics.
Main Methods:
- Review of current literature on exosome biology, engineering, and isolation technologies.
- Analysis of preclinical data on exosome-mediated drug delivery in breast cancer models.
- Examination of existing clinical trials involving exosome therapeutics in solid tumors.
Main Results:
- Exosomes demonstrate potential for enhanced therapeutic efficacy and reduced systemic toxicity in preclinical breast cancer models.
- Limited but increasing clinical trials are exploring exosome therapeutics for solid tumors.
- Significant gaps exist, including manufacturing standardization, pharmacokinetic data, and safety validation.
Conclusions:
- Exosomes represent a promising next-generation drug delivery platform for breast cancer treatment.
- Standardized manufacturing, further pharmacokinetic studies, and robust safety assessments are crucial for clinical translation.
- Harmonized methodologies and regulatory frameworks are essential for integrating exosome therapeutics into clinical oncology.
